Ligand Pharmaceuticals Incorporated (LGND)
Payables turnover
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Cost of revenue | US$ in thousands | 11,074 | 35,049 | 52,827 | 62,176 | 30,419 | 
| Payables | US$ in thousands | — | — | — | — | — | 
| Payables turnover | — | — | — | — | — | 
December 31, 2024 calculation
            Payables turnover = Cost of revenue ÷ Payables
            = $11,074K ÷ $—K
            = —        
Based on the provided data, it appears that there is no specific information available for Ligand Pharmaceuticals Incorporated payables turnover for the years ending December 31, 2020 through December 31, 2024. This lack of data suggests that it is not possible to analyze the company's payables turnover ratio for these periods. Additional information or financial data would be required to assess and interpret the payables turnover efficiency of Ligand Pharmaceuticals Incorporated during these years.
Peer comparison
Dec 31, 2024
Company name
                    Symbol
                    Payables turnover
                Ligand Pharmaceuticals Incorporated
                            LGND
                            —
                        Abbott Laboratories
                            ABT
                            —
                        AbbVie Inc
                            ABBV
                            —
                        ACADIA Pharmaceuticals Inc
                            ACAD
                            —
                        Alkermes Plc
                            ALKS
                            19.54
                        Amphastar P
                            AMPH
                            11.74
                        ANI Pharmaceuticals Inc
                            ANIP
                            —
                        Arcus Biosciences Inc
                            RCUS
                            8.33
                        Biomarin Pharmaceutical Inc
                            BMRN
                            —
                        Bristol-Myers Squibb Company
                            BMY
                            8.82
                        Catalyst Pharmaceuticals Inc
                            CPRX
                            —